-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the Guangdong Provincial Health Commission issued the "Guidelines for Household Medicine for Key Groups After Infection with the New Crown", and 28 proprietary Chinese medicines (17 exclusive varieties) were recommended
.
According to data from Minai.
com, the total sales scale of 28 proprietary Chinese medicines in China's three major terminal markets in 2021 exceeded 21.
6 billion yuan; The sales of 6 varieties exceeded 1 billion yuan, and "emergency miracle medicine" led with sales of more than 4.
2 billion yuan; There are more than 100 manufacturers of 3 proprietary Chinese medicines, and 2 exclusive varieties of Jichuan and Yiling are on the list
.
.
According to data from Minai.
com, the total sales scale of 28 proprietary Chinese medicines in China's three major terminal markets in 2021 exceeded 21.
6 billion yuan; The sales of 6 varieties exceeded 1 billion yuan, and "emergency miracle medicine" led with sales of more than 4.
2 billion yuan; There are more than 100 manufacturers of 3 proprietary Chinese medicines, and 2 exclusive varieties of Jichuan and Yiling are on the list
.
Guangdong issued the most comprehensive medication guidelines, covering the elderly, children and pregnant women
On December 26, the National Health Commission announced that the new coronavirus pneumonia was renamed the new coronavirus infection
.
On the same day, the "Overall Plan on the Implementation of "Class B and B Management" for Novel Coronavirus Infection issued by the Joint Prevention and Control Mechanism of the State Council pointed out that from January 8, 2023, "Class B and B Tube"
will be implemented for new coronavirus infection.
.
On the same day, the "Overall Plan on the Implementation of "Class B and B Management" for Novel Coronavirus Infection issued by the Joint Prevention and Control Mechanism of the State Council pointed out that from January 8, 2023, "Class B and B Tube"
will be implemented for new coronavirus infection.
After the adjustment of epidemic prevention measures, the number of infected cases may grow rapidly in the short term, so the procurement demand for symptomatic treatment drugs such as new crown-related traditional Chinese medicines, anti-new coronavirus small molecule drugs, antipyretic and cough suppressants will increase
sharply in the short term.
sharply in the short term.
In order to guide the public to prepare drugs on demand in a scientific and reasonable manner, the joint prevention and control mechanism of the State Council issued the "Reference Table of Common Drugs for Home Treatment of People with New Coronavirus Infection", the State Administration of Traditional Chinese Medicine issued the "Guidelines for Home Medicine Intervention of People with New Coronavirus Infection", and recently many regions in China have also released a drug catalogue
for people infected with new coronavirus infection.
for people infected with new coronavirus infection.
On December 27, the Health Commission of Guangdong Province issued the Guidelines for Household Medicine for Key Populations After Infection with the New Crown (the Guidelines), focusing on answering questions such as what symptoms may occur in key groups after being infected with the new crown, whether asymptomatic people need medication, and how to seek medical treatment for severe diseases.
Authoritatively answered the questions of household medicine for the elderly, children, and pregnant women after being infected with the new crown; Special reminders of common proprietary Chinese medicines and medication precautions
for key groups in home treatment.
Authoritatively answered the questions of household medicine for the elderly, children, and pregnant women after being infected with the new crown; Special reminders of common proprietary Chinese medicines and medication precautions
for key groups in home treatment.
28 proprietary Chinese medicines recommended! Throat and pediatric proprietary Chinese medicine have great potential
The Guidelines mention that for the new coronavirus infection or the common cold during the epidemic, whether it is prevention, treatment or early intervention, Chinese medicine has certain advantages
.
.
The Chinese proprietary medicines that can be used for the elderly with mild new coronavirus infection include Lianhua Qingwen, Lung Qingwen, Huo Xiang Zhengqi Water, etc.
(choose one proprietary Chinese medicine with similar functions); In the event of sore throat symptoms, commonly recommended drugs include double-material laryngeal wind dispersion, Liushen pills, open throat sword spray, clear throat drop pills, watermelon cream lozenges, etc
.
After fever, if the high fever does not subside for more than 3 days, Angong Niuhuang Pill can be used;
(choose one proprietary Chinese medicine with similar functions); In the event of sore throat symptoms, commonly recommended drugs include double-material laryngeal wind dispersion, Liushen pills, open throat sword spray, clear throat drop pills, watermelon cream lozenges, etc
.
After fever, if the high fever does not subside for more than 3 days, Angong Niuhuang Pill can be used;
Children with colds and other related symptoms, the optional Chinese proprietary medicines include children's soy qiaoqing heat granules, children's lung heat cough and asthma oral liquid, Lanqin oral liquid, children's Chai Gui antipyretic oral liquid, honeysuckle oral liquid, etc.
(choose one of the Chinese proprietary medicines with similar functions, but generally children with diarrhea do not choose).
(choose one of the Chinese proprietary medicines with similar functions, but generally children with diarrhea do not choose).
It is worth noting that for some special groups, including the elderly, infants and young children, people with underlying diseases and unvaccinated people, the Guidelines list commonly used proprietary Chinese medicines and precautions
for medication treatment at home.
for medication treatment at home.
Guidelines on household medicines for key groups after infection with the new crown (proprietary Chinese medicines)
According to the author's statistics, the Guangdong Provincial Health Commission issued the "Guidelines for Household Medicine for Key Groups After Infection with the New Crown", and there are a total of 28 proprietary Chinese medicines, of which 17 are exclusive varieties
.
.
After the new crown virus infection, many patients will have a sore throat and dry throat, and some even have pain like a knife
.
According to data from Minai.
com, the sales scale of throat proprietary Chinese medicine in China's three major terminal markets (see the end of this article for statistical scope) exceeded 9 billion yuan in 2021, a year-on-year increase of 3.
15%.
.
According to data from Minai.
com, the sales scale of throat proprietary Chinese medicine in China's three major terminal markets (see the end of this article for statistical scope) exceeded 9 billion yuan in 2021, a year-on-year increase of 3.
15%.
The prevention and treatment of children's new crown is a matter of great concern to parents, and children's proprietary Chinese medicines are also frequently listed in the drug lists
of major new crown virus infections.
According to data from Minai.
com, in 2021, the sales scale of pediatric proprietary Chinese medicines in China's three major terminal markets exceeded 14 billion yuan, a year-on-year increase of 38.
36%.
of major new crown virus infections.
According to data from Minai.
com, in 2021, the sales scale of pediatric proprietary Chinese medicines in China's three major terminal markets exceeded 14 billion yuan, a year-on-year increase of 38.
36%.
6 more than 1 billion varieties lead! 17 exclusive proprietary Chinese medicines stand out
According to data from Minai.
com, the total sales scale of 28 proprietary Chinese medicines in China's three major terminal markets in 2021 exceeded 21.
6 billion yuan.
Among them, the sales of 18 proprietary Chinese medicines exceeded 100 million yuan, the sales of 6 varieties exceeded 1 billion yuan, Angong Niuhuang Pill led with sales of more than 4.
2 billion yuan, the sales of Pudi Blue Anti-inflammatory Oral Liquid of Jichuan Pharmaceutical exceeded 2.
8 billion yuan, the sales of Pediatric Qiaoqiao Qinghu Granules exceeded 1.
9 billion yuan, the sales of Yangzijiang Pharmaceutical's Lanqin oral liquid exceeded 2.
5 billion yuan, and the sales of Lianhua Qingwen capsules and Lianhua Qingwen granules of Yiling Pharmaceutical exceeded 2.
3 billion yuan
.
com, the total sales scale of 28 proprietary Chinese medicines in China's three major terminal markets in 2021 exceeded 21.
6 billion yuan.
Among them, the sales of 18 proprietary Chinese medicines exceeded 100 million yuan, the sales of 6 varieties exceeded 1 billion yuan, Angong Niuhuang Pill led with sales of more than 4.
2 billion yuan, the sales of Pudi Blue Anti-inflammatory Oral Liquid of Jichuan Pharmaceutical exceeded 2.
8 billion yuan, the sales of Pediatric Qiaoqiao Qinghu Granules exceeded 1.
9 billion yuan, the sales of Yangzijiang Pharmaceutical's Lanqin oral liquid exceeded 2.
5 billion yuan, and the sales of Lianhua Qingwen capsules and Lianhua Qingwen granules of Yiling Pharmaceutical exceeded 2.
3 billion yuan
.
Market situation of 28 proprietary Chinese medicines
Among the 28 proprietary Chinese medicines, except for Guilin watermelon cream lozenges, lung cleansing and detoxification granules, and Pudi blue anti-inflammatory oral liquid, the remaining 25 varieties are all Class A/B varieties in the national medical insurance catalog, including 13 Class A and 12 Class B
.
.
The number of enterprises with approvals for 3 varieties is more than 100, specifically Huo Xiang Zhengqi Water, Cold Clearing Granules, and Angong Niuhuang Pill
.
Among them, there are as many as 162 manufacturers of Huoxiang Zhengqi Water, 129 manufacturers of cold and heat relief granules, and 120 manufacturers
of Angong Niuhuang Pill.
.
Among them, there are as many as 162 manufacturers of Huoxiang Zhengqi Water, 129 manufacturers of cold and heat relief granules, and 120 manufacturers
of Angong Niuhuang Pill.
The 17 proprietary Chinese medicines are exclusive varieties, including Yangzijiang Pharmaceutical's Lanqin Oral Liquid, Jichuan Pharmaceutical's Pudi Blue Anti-inflammatory Oral Liquid, Sanli Pharmaceutical's Open Throat Sword Spray, Sunflower Pharmaceutical's Pediatric Lung Fever, Cough and Asthma Oral Liquid, and Darentang's Clear Throat Drop Pill
.
Among them, Yiling Pharmaceutical has 2 exclusive varieties of Lianhua Qingwen capsules and Lianhua Qingwen granules on the list, and Jichuan Pharmaceutical has 2 exclusive varieties of Pediatric Soy Qingwei Granules and Pudi Blue Anti-inflammatory Oral Liquid on the list
.
.
Among them, Yiling Pharmaceutical has 2 exclusive varieties of Lianhua Qingwen capsules and Lianhua Qingwen granules on the list, and Jichuan Pharmaceutical has 2 exclusive varieties of Pediatric Soy Qingwei Granules and Pudi Blue Anti-inflammatory Oral Liquid on the list
.
Source: Minainet database, Guangdong Provincial Health Commission Note: Minai.
com "China's three major terminal six major market drug competition pattern", the statistical scope is: urban public hospitals and county-level public hospitals, urban community centers and township health centers, urban physical pharmacies and online pharmacies, excluding private hospitals, private clinics, village clinics, excluding county and rural pharmacies; The above sales are calculated
based on the average retail price of the product at the terminal.
If there is any omission in the data statistics, welcome to correct!
com "China's three major terminal six major market drug competition pattern", the statistical scope is: urban public hospitals and county-level public hospitals, urban community centers and township health centers, urban physical pharmacies and online pharmacies, excluding private hospitals, private clinics, village clinics, excluding county and rural pharmacies; The above sales are calculated
based on the average retail price of the product at the terminal.
If there is any omission in the data statistics, welcome to correct!
